WebMar 22, 2016 · We recommend appropriate standard dosing of the DOACs in patients with a BMI less than or equal to 40 kg m −2 and weight less than or equal to 120 kg for VTE treatment, VTE prevention, and prevention of ischemic stroke and systemic arterial embolism in non-valvular AF.; We suggest that DOACs should not be used in patients … WebAF and low body weight (#60 kg), DOACs showed JACC VOL. 73, NO. 8, 2024 Lee et al. MARCH 5, 2024:919– 31 DOAC in AF With Low Body Weight 929. better effectiveness and safety than warfarin. This result remained consistent in patients with extremely low body weight (<50 kg). Also, regular
Direct Oral Anticoagulant (DOAC) Initiation and Monitoring …
WebMar 26, 2024 · Anticoagulation treatment for DVT or PE in people at extremes of body weight (less than 50 kg or more than 120 kg) Body weight can influence the absorption, distribution and elimination of anticoagulants, and their therapeutic effect can be altered at extremes of body weight. WebDirect Oral Anticoagulants (DOACs) Can be substituted for warfarin in many instances and do not require bridging prior to becoming therapeutic unless oral intake is precluded (discuss with pharmacy). NOT approved in the setting of mechanical heart valves—per RE-ALIGN, rates of bleeding and thromboembolism are higher with dabigatran than warfarin. taseful
BMI influence on clinical outcomes for NVAF with DOACs thera
WebDOACs and Obesity • Minor impact of body weight on PK/PD of rivaroxaban • Levels of apixaban within expected range in obesity • Limited data for dabigatran, but considerable proportion of levels below expected range in obesity • Little impact of body weight on PK of edoxaban 19 J Thromb Haemost 2024;19:1874-82. WebThe International Society of Thrombosis and Haemostasis (ISTH) suggests that DOACs should not be used in patients with a Body Mass Index (BMI) > 40 kg/m2 or a weight >120kg, and if a DOAC is used in these … WebMar 6, 2024 · For patients with nonvalvular atrial fibrillation and extremely low body weight, direct oral anticoagulants (DOACs) are safer and more effective than warfarin, according to results published in the Journal of the American College of Cardiology. cm m rijtje